GENE EXPRESSION PROFILING AFTER ANGIOGENESIS INHIBITOR TREATMENT by Hanakova, Adela et al.
ORIGINAL RESEARCH 
 
33 
 
GENE EXPRESSION PROFILING AFTER ANGIOGENESIS INHIBITOR 
TREATMENT 
 
Adela Hanakova1,2, Klara Pizova1,2, Outi Huttala3, Jertta-Riina Sarkanen3,  
Tuula Heinonen3, Dagmar Jirova4, Kristina Kejlova4, Hana Kolarova1,2 
 
1Department of Medical Biophysics, Faculty of Medicine and Dentistry,  
Palacky University, Olomouc, Czech Republic 
2Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry,  
Palacky University, Olomouc, Czech Republic 
3Finnish Center for Alternative Methods, Medical School, University of Tampere, Tampere, Finland 
4National Institute of Public Health, Prague, Czech Republic 
 
 
 
Abstract 
The angiogenic process can be summarized as cell activation by a lack of oxygen releases angiogenic molecules that 
attract inflammatory and endothelial cells and promote their proliferation. Several protein fragments produced by the 
digestion of the blood-vessel walls intensify the proliferative activity of endothelial cells. Acetyl salicylic acid is often 
used as an analgesic drug to relieve minor aches and pains, a drug with antitumour activity and an anti-inflammatory 
medication. In our experiments we propose using the angiogenesis model and photodynamic therapy (PDT) for 
observing changes in angiogenesis after treatment, and also for increasing the effect of PDT by addition of 
angiogenesis inhibitors. 
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Introduction 
 The vascular network regulates the body homeostasis 
by transporting oxygen, liquids, nutrients, cells and 
signaling molecules to all part of the body and 
disposing of waste from the tissues [1]. 
 Normal blood vessel formation takes place in two 
main ways by: vasculogenesis and angiogenesis [2, 3]. 
 Vasculogenesis is the differentiation de novo of 
vascular endothelial cells from precursor cells known 
as angioblasts during embryonic development [4]. The 
endothelial cell lattice created by vasculogenesis then 
serves as a scaffold for abiogenesis [3]. 
 Angiogenesis is the formation of new capillary 
sprouts from pre-existing blood vessels [5]. After the 
primary capillary plexus is formed, it is remodeled by 
the sprouting and branching of new vessels from 
preexisting ones. The normal mechanism of 
angiogenesis depends on the coordination of several 
independent processes, for example removal of 
pericytes from the endothelium and destabilization of 
the vessel by angiopoietin-2 (Ang2) and shift of 
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endothelial cells from a stable, growth-arrested state to 
a plastic, proliferative phenotype [3]. 
 VEGF is other candidate as a potential regulator of 
angiogenesis. This emanates from the fact that VEGF 
is a secreted protein, its binding sites are selectively 
expressed in endothelial cells in vitro and in vivo and 
the expression of its mRNA correlates with blood 
vessel growth. Vascular endothelial growth factor 
(VEGF, VEGF-A) is a major regulator of physiological 
and pathological angiogenesis. Several VEGF 
inhibitors have been approved by the FDA for the 
treatment of advanced cancer and neovascular age-
related macular degeneration [6]. Further, vascular 
endothelial growth factor (VEGF)-induced hyperper-
meability allows for local extravasation of proteases 
and matrix components from the bloodstream [3]. 
 Angiogenesis is also stimulated by fibroblast growth 
factor (FGF) [4]. FGF is synthesized and secreted by 
human adipocytes and the concentration of bFGF 
correlates with the BMI in blood samples [7]. 
Additionally, bFGF is a critical component of human 
embryonic stem cell culture medium; the growth factor 
is necessary for the cells to remain in an 
undifferentiated state, although the mechanisms by 
which it does this are poorly defined [8].   
 It must be pointed out, that the remodelling and 
growth of the vasculature is a normal bodily process, 
particularly in wound healing, in pathological disease 
processes such as cancer and in the female menstrual 
cycle and hence in certain cases it may be important 
that the effects of gene therapy, once delivered, are 
strictly controlled [3, 4, 9].  
 One potentially useful toxic gene product is the 
tumour necrosis factor-?? ????-???????-? is toxic for 
proliferating, but not quiescent, microvascular 
endothelium. TNF-?? ??? ??? ??????? ??????? ???? ??????????
needs to be regulated at a transcriptional level. 
However, its wide-ranging toxicity against tumours 
make it well worth further investigation [9]. 
 Another interesting gene platelet-derived growth 
factor (PDGF) is released in high concentrations during 
tissue repair and inflammatory processes, first from 
platelet alpha granules and subsequently by activated 
macrophages. Other peptide growth factors that have 
been shown to be actively released from platelets and 
activated macrophages, together with PDGF, include 
epidermal growth factor (EGF), transforming growth 
factor (TGF)-alpha, TGF-beta, and basic fibroblast 
growth factor (bFGF) [10].  
 
 
Experiments 
 The study aimed to investigate the use of acetyl 
salicylic acid (ASA) for inhibiting angiogenesis  
(angiogenesis model in vitro was designed by a 
scientific team from FICAM). The experiments were 
carried out with co-culture of two types of cells: hASC 
(human adipose stem cells, 22 000 cells/well) and 
HUVEC (human umbilical vein endothelial cells, 4 000 
cells/well). Cells were treated with 1mM ASA in 
concentrations 2, 1, 0.5, 0.25 and 0.125 mmol/l.  
 Second, the isolation of RNA was performed using 
RNeasy mini kit (Qiagen). Consequently RNA was 
transcribed to cDNA (RT2 Prolifer PCR Array). 
Finally, real-time PCR was carried out using 96-well 
array: 84 target genes, 5 reference genes and 7 control 
genes. The expression of genes was assessed using the 
program BIO-RAD CFX Manager.  
 Graphs 1–7 show the first results of real-time PCR 
for selected interesting genes only. All results represent 
samples treated by ASA. The experiments were 
performed using 96-well arrays.  
 Graphs 1, 2 and 3 show the the curves of three 
selected reference genes Beta-2-microglobulin, very 
often used Glyceraldehyde-3-phosphate dehydrogenace 
and Hypoxanthine phosphoribosyltransferase.   
 The amplification curve (graph 4) is for Fibroblast 
growth factor 2 (FGF2) which mediates the formation 
of new blood vessels (angiogenesis) during wound 
healing of normal tissues and tumour development. It is 
an important mediator responsible for induction of 
endothelial precursor cells from the mesoderm [11]. It 
is apparent that the FGF2 amplification curve began to 
increase several cycles after reference curves but it is 
still very early to draw any conclusions. 
 Angiopoietin 1 (graph 5) is an important protein 
because of its role in vascular development and 
angiogenesis. Its amplification curve predicates very 
high and early expression. It plays a critical role in 
mediating reciprocal interactions between the 
endothelium and surrounding matrix and mesenchyme 
[12, 13]. 
 Platelet-derived growth factor alpha (graph 6) 
polypeptide is the factor for cells of mesenchymal 
origin. 
 ???????????????????? ??????? ?????? ??????? ??????????
is a ligand for the epidermal growth factor receptor and 
activates a signaling pathway for cell proliferation, 
differentiation and development [14].    
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Fig. 1: Curve of Beta-2-microglobulin. 
 
 
 
Fig. 2: The curve of Glyceraldehyde-3-phosphate dehydrogenace. 
 
 
Fig. 3: The curve of Hypoxanthine phosphoribosyltransferase. 
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Fig. 4: The curve of Fibroblast growth factor 2 (basic). 
 
 
 
Fig. 5: Curve of Angiopoetin 1. 
 
 
Fig. 6: The curve of Platelet-derived growth factor alpha polypeptide. 
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Fig. 7: The curve of Transforming growth factor alpha ??????. 
 
 
Conclusion 
 Our research laboratory is focused on photodynamic 
therapy (PDT) in vitro. This combinates visible light of 
an appropriately wavelength and non-toxic chemical 
agent called photosensitiser. This combination is used 
to destroy cancer cells or to eradicate bacterial cells 
[15-25].    
 Currently new strategies and alternatives are needed 
to increase the options for treatment of cancer. 
Photodynamic therapy (PDT) has become 
progressively established as a mode of treatment of 
malignant as well as non-malignant diseases which are 
characterized by the occurrence of unwanted or 
harmful cells [26].    
 Combining angiogenic inhibitors with chemotherapy 
and radiotherapy has demonstrated the potential to be 
an attractive and effective approach to cancer 
treatment. Ferrario and colleagues first demonstrated 
that PDT efficacy could be enhanced by combining 
angiogenic inhibitors with the treatment regimen [27]. 
 Acetylsalicylic acid (ASA, aspirin) appears to be a 
significant inhibitor of angiogenesis. It has remained 
the most commonly-used drug for relieving pain, 
inflammatory symptoms, and fever. Recently, ASA has 
been shown to reduce the risk for colorectal cancer by 
as much as 40%, a property that is shared with other 
nonsteroidal anti-inflammatory drugs (NSAIDS) [28].  
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